CURRICULUM VITAE

MICHEL MICHAELIDES

Date of birth: 1 January 1973

Present Appointment

2010-	Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London and Clinical Senior Lecturer, UCL Institute of Ophthalmology, London

Previous Appointments

2009-2010	Ocular Genetics and Paediatric Ophthalmology Fellowships Casey Eye Institute, Portland, Oregon, USA
2008-2009	Medical Retina Fellowship, Moorfields Eye Hospital, London
2007-2008	Specialist Registrar, Moorfields Eye Hospital, London
2006-2007	Specialist Registrar, Charing Cross University Hospital, London
2005-2006	Specialist Registrar, Moorfields Eye Hospital, London
2004-2005	Specialist Registrar, Whipps Cross University Hospital, London
2002-2004	Clinical Research Fellow, Institute of Ophthalmology & Moorfields Eye Hospital, Professors A.T. Moore, D.M. Hunt & J.D. Mollon

Qualifications

1994	Intercalated BSc Pharmacology, 1st Class (Kings College London)
1997	MB BS (Kings College London)
2001	MRCOphth
2004	MD (University College London)
2008	FRCOphth
2012	FACS

Awards and Prizes

1993	Inchley Prize in Pharmacology
	Medical Research Council Scholarship for Intercalated BSc
1994	Astra Prize for Cardiovascular Pharmacology
	Zeneca Prize for Best Intercalated Medical Student
1996	Cargill Prize in Ophthalmology
	Legg Prize in Surgical Pathology
1997	Oram Prize in Cardiology
	Blair-Bell Prize in Gynaecology
	Almond Prize in Diseases of Children
2010	International Guest Scholar, American College of Surgeons
	Department of Health/HEFCE 'New Blood' Senior Lectureship Award
2011	Foundation Fighting Blindness Career Development Award
2013	Elected to The Macula Society
	Elected to The British Eye Study Group

Selected Current Research Grants

Foundation Fighting Blindness (USA) (07/11-07/16; $375,000): Career Development Award - Phenotyping and genotyping adults and children with inherited retinal dystrophies to probe relationships between retinal function and structure, in preparation for planned therapeutic interventions (gene- and stem cell-based, and pharmacological): to M Michaelides

National Institute for Health Research (06/12-06/17; £1,968,305) Programme Grant for Applied Research: Towards an evidence-based clinical management of visual hallucinations: prevalence, prognosis, impact and pathophysiology. Co-PI.

Wellcome Trust (2012-2017; £737,353) Multi-User Equipment Grant: Animal and human high resolution retinal imaging: to RR Ali, ME Cheetham, F Cordiero, J Greenwood, K Matter, M Michaelides, SE Moss, G Rees, AR Webster. Lead PI on Human Imaging.

British Retinitis Pigmentosa Society (*RP Fighting Blindness*) (08/11-07/16; £747,085): BRPS centre for the development of gene therapy for inherited retinal dystrophies: to RR Ali, J Bainbridge and M Michaelides.

National Eye Institute (NEI) of the National Institutes of Health (NIH) (R01EY017607; 09/13-09/17; $312,000): Assessing photoreceptor structure and function: to J Carroll and M Michaelides.

Medical Research Council (07/13-06/18; £2,152,639): Clinical trial of gene therapy for the treatment of achromatopsia: to RR Ali, J Bainbridge and M Michaelides.

National Institute for Health Research (2013-2015; £200,000) Rare Diseases Translational Research Collaboration: In-depth phenotyping of Stargardt disease: to M Michaelides, AT Moore and AR Webster.

Foundation Fighting Blindness (USA) (2010-2015; $1,302,000) Centre Grant: Research Center for the Study of Retinal Degenerative Diseases at UCL Institute of Ophthalmology and Moorfields Eye Hospital: to RR Ali, SS Bhattacharya, AC Bird, FW Fitzke, GE Holder, M Michaelides, AT Moore, AG Robson, AR Webster.

Fight for Sight and Biomedical Research Centre (2011-2013; £30,000): Phenotyping and genotyping patients with achromatopsia in preparation for gene therapy trials: to M Michaelides (PI).

Macular Disease Society (2011-2014; £35,000): The use of massively-parallel polynucleotide sequencing to determine complete genomic DNA sequence of a region incorporating the ABCA4 gene in probands with inherited macular disease: to M Michaelides, AT Moore and AR Webster.

Novartis (2011-2014; £205,276): An exploratory study of Ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema: to N Okhravi and M Michaelides.

Moorfields Special Trustees (2011-2014; £65,879): A Prospective Clinical Study of the Effects of Panretinal Argon Photocoagulation Delivered with the Pascal Photocoagulator (OptiMedica, Santa Clara, CA, USA) on Retinal Sensitivity in Patients with Proliferative Diabetic Retinopathy

Selected Current Clinical Trials

1. Principal Investigator, Moorfields Eye Hospital.
To Investigate the Efficacy and Safety of Ranibizumab (Lucentis) in Uveitic Macular Oedema
http://clinicaltrials.gov/ct2/show/NCT01564108?term=michaelides&rank=2

2. Principal Investigator, Moorfields Eye Hospital.
A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy
http://clinicaltrials.gov/ct2/show/NCT01345006?term=stargardt&rank=3

3. Principal Investigator, Moorfields Eye Hospital.
A Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)
http://clinicaltrials.gov/ct2/show/NCT01014052?term=lrat&rank=1

Selected Recent Publications

I have over 105 peer-reviewed publications since 2001 and 16 co-authored book chapters relating to retinal disease. My Google Scholar h-index is 26, i10-index of 53, with 2030 citations in total.

1. Retinal Structure and Function in Achromatopsia: Implications for Gene Therapy.
   Sundaram V, Wilde C, Aboshiha J, Cowing J, Han C, Langlo CS, Chana R, Davidson AE, Sergouniotis PI, Bainbridge JW, Ali RR, Dubra A, Rubin G, Webster AR, Moore AT, Nardini M, Carroll J, **Michaelides M**.
   Ophthalmology 2014;121(1):234-45.

2. A Longitudinal Study of Stargardt Disease: Quantitative Assessment of Fundus Autofluorescence, Progression and Genotype Correlations.
   Fujinami K, Lois N, Mukherjee R, McBain VA, Tsunoda K, Tsubota K, Stone EM, Fitzke FW, Bunce C, Moore AT, Webster AR, **Michaelides M**.
   Invest Ophthalmol Vis Sci. 2013; 54(13):8181-90.

3. Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4).
   Sivaprasad S, Crosby-Nwaobi R, Esposti S, Peto T, Rajendram R, **Michaelides M**, Hykin P.
   PLoS One. 2013;8(8):e72755.

4. ABCA4 Gene Screening by Next-Generation Sequencing in a British Cohort.
   Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, Tsubota K, Webster AR, Moore AT, Allikmets R, **Michaelides M**.
   Invest Ophthalmol Vis Sci. 2013;54(10): 6662-74.

5. A Longitudinal Study of Stargardt Disease: Clinical and Electrophysiologic Assessment, Progression, and Genotype Correlations.
   Fujinami K, Lois N, Davidson AE, Mackay DS, Hogg CR, Stone EM, Tsunoda K, Tsubota K, Bunce C, Robson AG, Moore AT, Webster AR, Holder GE, **Michaelides M.**
   Am J Ophthalmol. 2013;155(6):1075-1088.

6. The Clinical Effect of Homozygous ABCA4 Alleles in 18 Patients.
   Fujinami K, Sergouniotis PI, Davidson AE, Mackay D, Tsunoda K, Tsubota K, Robson A, Holder GE, Moore AT, **Michaelides M**, Webster AR.
   Ophthalmology *2013*;120(11):2324-31.

7. The Effect of Cone Opsin Mutations on Retinal Structure and the Integrity of the Photoreceptor Mosaic.
   Carroll J, Dubra A, Gardner JC, Mizrahi-Meissonnier L, Cooper RF, Dubis AM, Nordgren R, Genead M, Connor TB Jr, Stepien KE, Sharon D, Hunt DM, Banin E, Hardcastle AJ, Moore AT, Williams DR, Fishman G, Neitz J, Neitz M, **Michaelides M**.
   Invest Ophthalmol Vis Sci. 2012;53(13):8006-15.